Amgen’s $900K Options Bet: Why This Biotech Giant Is Exploding NOW!
Did you know a single options trade recently collected a massive $900,000 premium on Amgen shares, signaling extreme confidence in its future? This bold move underpins a compelling bullish thesis for Amgen Inc., suggesting the biotech giant is rapidly transitioning from a defensive dividend play to a growth-oriented leader. The company recently delivered strong Q4 results and provided robust 2026 revenue guidance, fueled by impressive growth in treatments like Repatha and the high anticipation for its obesity candidate, MariTide. Furthermore, despite its solid financials and expanding pipeline, Amgen's valuation appears highly attractive, especially when considering the significant cushion provided by the options trade's strike price. Discover how market experts are positioning themselves for potential re-ratings and stay ahead of the curve by subscribing to our channel for more exclusive investment insights.
Tags/Hashtags: #amgen #maritide #valuation #pharma #amgn #oppcost
Leave a Reply